within Pharmacolibrary.Drugs.N_NervousSystem.N05C_HypnoticsAndSedatives.N05CM05_Scopolamine;

model Scopolamine_1
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C(
    weight = 70,
    F = 1,
    Cl = 1.886111111111111e-05,
    adminDuration = 600,
    adminMass = 1.5 / 1000000,
    adminCount = 1,
    Vd = 0.0046,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Scopolamine_1</td></tr><tr><td>ATC code:</td><td>N05CM05_1</td></tr><td>route:</td><td>transdermal</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>1.5</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>4.6</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.97</td><td>L/h/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Scopolamine is an anticholinergic agent used to prevent motion sickness and postoperative nausea/vomiting. It blocks the action of acetylcholine on smooth muscles, glands, and in the central nervous system.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics reported in healthy males and females after transdermal administration (1.5 mg/patch, delivering approximately 1 mg over 3 days).</p><h4>References</h4><ol><li><p>Delgado-Charro, MB, &amp; Guy, RH (2014). Effective use of transdermal drug delivery in children. <i>Advanced drug delivery reviews</i> 73 63–82. DOI:<a href=\"https://doi.org/10.1016/j.addr.2013.11.014\">10.1016/j.addr.2013.11.014</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/24333231/\">https://pubmed.ncbi.nlm.nih.gov/24333231</a></p></li><li><p>Berner, B, &amp; John, VA (1994). Pharmacokinetic characterisation of transdermal delivery systems. <i>Clinical pharmacokinetics</i> 26(2) 121–134. DOI:<a href=\"https://doi.org/10.2165/00003088-199426020-00005\">10.2165/00003088-199426020-00005</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/8162656/\">https://pubmed.ncbi.nlm.nih.gov/8162656</a></p></li><li><p>Guay, DR (2003). Clinical pharmacokinetics of drugs used to treat urge incontinence. <i>Clinical pharmacokinetics</i> 42(14) 1243–1285. DOI:<a href=\"https://doi.org/10.2165/00003088-200342140-00004\">10.2165/00003088-200342140-00004</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/14606931/\">https://pubmed.ncbi.nlm.nih.gov/14606931</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.N.N05CM05_1 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Scopolamine_1;
